Pelvital USA, Inc., a leading innovator in women's health, is pleased to announce the successful closing of an additional $2.32 Million in its seed-plus funding round, closing the round out $500,000 oversubscribed at $5 Million. The seed plus funding will be instrumental in expediting the commercialization of Flyte, Pelvital's novel FDA-cleared revolutionary, accessible, and clinically proven treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles..

作为女性健康领域的领先创新者，Pelvital USA，Inc.很高兴地宣布，其seed plus融资回合成功完成了232万美元的额外资金，结束了以500万美元超额认购50万美元的这轮融资。seed plus资金将有助于加速Flyte的商业化，Flyte是Pelvital的新型FDA批准的革命性，可获得且经临床验证的治疗压力性尿失禁（SUI）和盆底肌肉无力的疗法。